SIBO (small intestinal bacterial overgrowth): the AU general practice approach

Small intestinal bacterial overgrowth (SIBO) is a clinical syndrome caused by excessive bacteria colonising the small intestine — an environment that is normally near-sterile. The dominant symptoms are bloating, visible abdominal distension that worsens through the day, postprandial gas and cramping, and altered bowel habit. The methane-producing variant, now formally termed intestinal methanogen overgrowth (IMO), is dominated by the archaeon Methanobrevibacter smithii and typically manifests with constipation rather than diarrhoea.

The small intestine stays near-sterile in healthy people through a combination of gastric acid, bile salts, peristalsis (the migrating motor complex), the ileocaecal valve, and mucosal immunity. When any of these mechanisms fail — through surgery, motility disorders, acid-suppressing drugs, or chronic systemic disease — colonic-type bacteria migrate upward into the small intestine and ferment ingested carbohydrates, producing gas and, in severe cases, impairing nutrient absorption (B12 depletion, fat malabsorption, iron deficiency).

True SIBO prevalence is unknown and depends heavily on the diagnostic criterion used. In specialist gastroenterology clinics evaluating irritable bowel syndrome, breath-test positivity rates of 30–60% have been reported — but clinically significant SIBO requiring antibiotic treatment is considerably rarer. Over-diagnosis is a genuine problem: a positive breath test in an otherwise healthy person with non-specific bloating, no structural risk factor, and no identifiable functional cause often reflects a false-positive or a functional GI diagnosis rather than true SIBO. The Gastroenterological Society of Australia (GESA) and international gastroenterology bodies are aligned on the principle: establish the predisposing cause before diagnosing SIBO, and treat the patient’s clinical picture rather than the breath-test number alone.

A. Core clinical — the AU general practice framework

History

A detailed bowel, surgical, and medication history is the foundation — the predisposing factor almost always reveals itself.

• Symptom pattern — bloating and distension (postprandial timing, worsening through the day), excessive gas (belching, flatulence), stool consistency and frequency (diarrhoea = hydrogen-dominant SIBO; constipation = IMO), steatorrhoea (pale, floating, malodorous stools — signals bile-salt deconjugation or secondary pancreatic insufficiency).
• Surgical history — any prior GI surgery matters even decades later: Roux-en-Y gastric bypass (SIBO prevalence up to 30%), small-bowel resection, ileocaecal resection, cholecystectomy, anti-reflux surgery, bariatric procedures.
• Medication review — chronic opioid use impairs the migrating motor complex and is a leading reversible cause; long-term proton pump inhibitor use (months to years) reduces gastric acid; anticholinergics; GLP-1 receptor agonists (associated with gastroparesis). SafeScript review for opioid-using patients is appropriate.
• Underlying disease screen — diabetes (autonomic neuropathy and gastroparesis), scleroderma (up to 40–60% of patients with systemic sclerosis develop SIBO), chronic pancreatitis, coeliac disease, inflammatory bowel disease, cirrhosis, common variable immunodeficiency.
• Yellow flags — unintentional weight loss, rectal bleeding, nocturnal symptoms, new symptom onset over age 50 years, family history of colorectal cancer or inflammatory bowel disease.

Investigations

First-line pathology to exclude differential diagnoses and detect nutritional consequences:

• FBC — iron deficiency anaemia, macrocytic anaemia (B12 depletion).
• Ferritin, B12, folate — classical SIBO pattern: low B12, normal or elevated folate (bacteria produce folate while competing for B12).
• Calcium, magnesium, fat-soluble vitamins (A, D, E, K), INR — markers of fat malabsorption.
• TSH, HbA1c — alternative motility aetiology.
• Coeliac serology — tTG IgA plus total IgA.
• Faecal calprotectin — exclude inflammatory bowel disease if change in stool habit.
• Faecal elastase — exclude pancreatic exocrine insufficiency, especially with steatorrhoea.

Diagnostic test — hydrogen/methane breath test (HMBT)

The HMBT is the most pragmatic diagnostic option in Australian general practice. Per the North American Consensus (Rezaie et al., AJG 2017), the patient fasts overnight, prepares with a 24-hour low-FODMAP diet, drinks glucose 75 g or lactulose 10 g, and provides breath samples every 15–20 minutes for 90–180 minutes.

Positive criteria:

• SIBO: rise ≥20 ppm hydrogen above baseline within 90 minutes.
• IMO: methane ≥10 ppm at any point.

The test has no Medicare item number — private pathology labs charge approximately $80–150 out-of-pocket. Glucose substrate offers better specificity (preferentially absorbed in the proximal small intestine); lactulose offers broader sensitivity but poorer specificity because of transit variability. Reproducibility is modest — treat the clinical picture alongside the test result.

Management

Step 1 — Address the predisposing cause. This determines whether SIBO recurs.

• Deprescribe or minimise opioids and long-term proton pump inhibitors (consider H2-blocker as substitute).
• Optimise glycaemic control in diabetic gastroparesis.
• Consider prokinetic therapy for motility-driven SIBO — prucalopride is PBS Authority-listed for chronic constipation and is sometimes used for motility-impaired SIBO under specialist guidance; options are limited in Australia.
• Surgical referral for anatomical causes (blind-loop, fistula, stricture).
• Replete nutritional deficiencies — B12 (oral or intramuscular), iron, fat-soluble vitamins.

Step 2 — Antibiotic eradication (14-day course). Per eTG and the ACG 2020 SIBO guideline:

• Rifaximin 550 mg three times daily × 14 days — first-line. Minimal systemic absorption; favourable safety profile. In Australia, rifaximin is PBS Authority only for hepatic encephalopathy — for SIBO it requires a private prescription (~$300–400 per course).
• Ciprofloxacin 500 mg twice daily × 14 days — PBS general; weigh antimicrobial stewardship and tendon/QT risks.
• Metronidazole 400 mg three times daily × 14 days — PBS general; covers anaerobes; alcohol abstinence required.
• Amoxicillin-clavulanate 875/125 mg twice daily × 14 days — PBS general; broad cover.
• For IMO (methane-positive) — rifaximin combined with neomycin 500 mg twice daily, or rifaximin plus metronidazole, is more effective than rifaximin alone.

Step 3 — Plan for recurrence. Approximately 40% of patients relapse within nine months. Cyclical retreatment courses may be used in motility-driven SIBO under specialist direction. A low-FODMAP diet reduces fermentable substrate and symptom burden between courses (see Section C).

Differential diagnosis

Key differentials in general practice include IBS-D (no structural predisposition, Rome IV criteria; significant overlap), lactose and fructose intolerance (substrate-specific breath tests, food-linked symptoms), coeliac disease (positive serology, villous atrophy), microscopic colitis (non-bloody diarrhoea, biopsy-diagnosed), chronic pancreatitis (steatorrhoea, low faecal elastase), bile acid diarrhoea (post-cholecystectomy), and gastroparesis (early satiety, gastric emptying study).

B. Breath testing accuracy and antibiotic evidence

Limitations of breath testing. The hydrogen/methane breath test has important limitations that general practitioners need to understand before acting on results.

Reproducibility is modest — test-retest studies show clinically meaningful intra-individual variation without any treatment in between. The substrate choice carries a trade-off: glucose is more specific but misses distal SIBO; lactulose is more sensitive but susceptible to transit-dependent false-positive peaks. Preparation heavily influences baseline hydrogen — patients who have not followed the dietary preparation, who smoked on the morning of the test, or who exercised before testing will have unreliable results. The AGA Clinical Practice Update (Quigley, Gastroenterology 2020) emphasises that the breath test should support, not drive, the clinical decision — a positive test without a clear predisposing factor should prompt re-evaluation rather than automatic antibiotic prescribing.

Rifaximin efficacy. The systematic review and meta-analysis by Gatta and Scarpignato (Aliment Pharmacol Ther 2017) pooled 32 studies (over 2,500 patients) and found rifaximin achieved breath-test normalisation in approximately 70% of cases, compared with around 33% for systemic antibiotics and 10% for placebo. Rifaximin’s minimal systemic absorption limits adverse effects and drug interactions, and clinical resistance development has been low. The Australian prescribing context — PBS restriction to hepatic encephalopathy — means most GPs must weigh rifaximin’s superior efficacy against the significant private cost barrier.

SIBO and irritable bowel syndrome. The TARGET 1 and 2 randomised controlled trials (Pimentel et al., NEJM 2011) showed that empirical rifaximin (without breath testing) improved adequate relief of bloating in IBS-D compared with placebo (40.7% vs 31.7%, p<0.001). This suggests a subset of IBS-D patients have small-bowel bacterial dysbiosis responding to non-absorbed antibiotics, but this approach should be discussed carefully with each patient — antimicrobial stewardship and the absence of diagnostic confirmation are relevant considerations.

Emerging entity: hydrogen sulphide SIBO. Diarrhoea with sulfurous eructation suggests hydrogen sulphide-producing SIBO — an emerging entity not detectable on standard Australian breath tests, which measure only H₂ and CH₄. Clinicians should be aware this gap exists when breath testing is negative in a high-suspicion clinical picture.

C. Diet and adjunctive approaches

Low-FODMAP diet. The Monash University FODMAP framework involves a 4–6 week elimination of highly fermentable carbohydrates (oligosaccharides, disaccharides, monosaccharides, and polyols), followed by structured supervised reintroduction with a trained dietitian. Multiple randomised controlled trials support low-FODMAP for IBS-bloating — the evidence is reasonably extrapolated to SIBO-associated bloating, where reducing available fermentable substrate limits bacterial gas production. Low-FODMAP is a useful symptomatic adjunct and can bridge between antibiotic courses; it is not eradicative. Prolonged restriction without reintroduction risks micronutrient inadequacy and unnecessary dietary limitation — dietitian involvement is strongly recommended.

Elemental diet. Semi-elemental formula feeds (pre-absorbed amino acids, simple carbohydrates, lipids) essentially starve small-bowel bacteria of fermentable substrate. Case-series data suggest eradication rates exceeding 80% over 14–21 days. However, the absence of randomised controlled trial evidence, poor palatability, and significant cost limit elemental diet to refractory or relapsed cases under gastroenterologist and dietitian supervision.

Probiotics. Evidence for probiotics in SIBO is mixed — some strains (particularly Lactobacillus species) worsen bloating and gas in some patients. Probiotics are generally not recommended as primary SIBO treatment; selective adjunctive use under clinical guidance is reasonable for specific symptom management.

Herbal antimicrobials. Oregano oil, berberine, and allicin-based preparations are used in integrative settings. Small comparative trials against rifaximin exist, but product standardisation is poor and evidence is insufficient to recommend as first-line treatment where true SIBO is confirmed.

Gut-directed psychological therapy. Gut-brain axis dysfunction contributes to functional bloating and may perpetuate symptoms in the SIBO-IBS overlap population. CBT delivered by a psychologist via a Mental Health Treatment Plan (item 2715) may assist with the functional component.

D. Australian operations

Medicare and out-of-pocket costs. The hydrogen/methane breath test carries no Medicare item number — it is entirely patient-funded at approximately $80–150 through private pathology networks. Standard general practice attendances use consultation items (items 23, 36, 44). For eligible patients with chronic SIBO and an established predisposing condition (scleroderma, gastroparesis, post-bariatric surgery), the GP Chronic Condition Management Programme items (965 for preparation, 967 for review) can support allied health referral — including dietitian access for supervised low-FODMAP management.

PBS prescribing reality for SIBO:

Drug	PBS status for SIBO	Approximate patient cost
Rifaximin 550 mg	Private prescription only	~$300–400 per 14-day course
Ciprofloxacin 500 mg BD	PBS general	Co-payment only
Metronidazole 400 mg TDS	PBS general	Co-payment only
Amoxicillin-clavulanate 875/125 mg	PBS general	Co-payment only

The Australian Prescriber article on rifaximin provides detailed context on the PBS restriction to hepatic encephalopathy. When rifaximin cost is prohibitive, PBS-listed alternatives are clinically appropriate — discuss the efficacy trade-off with the patient as part of shared decision-making.

Referral pathways. Routine gastroenterology referral is appropriate for refractory or relapsing SIBO (two or more eradication courses without sustained remission), diagnostic uncertainty, suspected motility disorder, post-bariatric complications, or short-bowel syndrome. Major Australian gastroenterology centres with motility and SIBO interest include units at Westmead Hospital (Sydney), Royal Adelaide Hospital, Royal Brisbane and Women’s Hospital, and Royal Melbourne Hospital. Telehealth gastroenterology consultation applies the existing-relationship rule.

Mental Health Care Plan. Chronic GI symptoms — particularly bloating and altered bowel habit — frequently co-occur with anxiety and depression. A Mental Health Treatment Plan (item 2715) for psychology referral is appropriate when psychological distress is a significant component of the presentation.

E. Special populations

Post-bariatric surgery. Roux-en-Y gastric bypass creates anatomical blind limbs and significantly alters small-bowel motility — SIBO prevalence reaches up to 30% in this population. Symptoms may be attributed to dumping syndrome, reactive hypoglycaemia, or nutritional deficiencies unless SIBO is specifically considered. Management requires bariatric surgery follow-up, dietitian review, and SIBO treatment alongside nutritional optimisation.

Older adults. Age-related decline in gastric acid secretion, small-bowel motility (migrating motor complex attenuation), and mucosal immunity predisposes to SIBO. Polypharmacy — particularly opioids, anticholinergics, and long-term proton pump inhibitors — adds compounding risk. B12 deficiency from bacterial competition may be mistakenly attributed solely to age-related atrophic gastritis. Careful medication review and nutritional assessment are priorities. Antibiotic selection should account for renal function and drug interactions.

Scleroderma and systemic sclerosis. SIBO affects 40–60% of patients with systemic sclerosis, driven by smooth-muscle atrophy and neural plexus involvement producing severe hypomotility. Cyclical antibiotic rotation, prokinetics (under specialist guidance), and elemental feeding are often required. Symptoms may be difficult to separate from other GI manifestations of systemic sclerosis, and management should be coordinated between rheumatology and gastroenterology.

Pregnancy. SIBO management in pregnancy is complex — rifaximin, ciprofloxacin, and metronidazole all carry pregnancy restrictions. Nutritional support (B12, folate, iron, fat-soluble vitamins) is prioritised, and any antibiotic decision should involve the obstetric team and gastroenterologist. Emerging SIBO in pregnancy warrants early specialist referral.

When to escalate

Refer to gastroenterology for:

• Refractory or relapsing SIBO — two or more eradication courses without sustained remission.
• Diagnostic uncertainty — breath testing inconclusive or clinical picture inconsistent with SIBO.
• Suspected underlying motility disorder requiring specialist evaluation (gastric emptying study, small-bowel manometry, MRI follow-through).
• Post-bariatric surgery with recurrent GI symptoms.
• Short-bowel syndrome, intestinal fistula, or blind-loop anatomy.
• Marked unintentional weight loss, steatorrhoea not explained by coeliac or pancreatic insufficiency, or elevated faecal calprotectin.
• Nutritional collapse — severe malnutrition or B12-related neurological features.

Seek urgent assessment for dehydration or electrolyte derangement from profuse diarrhoea, and for suspected sepsis (fever, rigors, haemodynamic change) — rare in SIBO but possible in severely immunocompromised patients.

What this article is and is not

This is general health information drawn from Australian general practice and gastroenterology guidelines — eTG, AMH, RACGP publications, GESA resources, ACG 2020 SIBO guideline, and AGA 2020 Clinical Practice Update. It is not personal medical advice and does not create a doctor–patient relationship. Treatment decisions — including antibiotic prescribing and diagnostic testing — require individual assessment by your GP or specialist.

For Australian consumer information: HealthDirect — bloating, Better Health Channel — wind and flatulence, Monash University FODMAP resources.

---

Sources cited

1. RACGP AJGP — Barrett & Gibson, Fructose and lactose testing
2. Therapeutic Guidelines (eTG) — Antibiotic: chronic GI infection
3. Australian Medicines Handbook (AMH)
4. Australian Prescriber — rifaximin for hepatic encephalopathy
5. Gastroenterological Society of Australia (GESA)
6. Monash University FODMAP resources
7. HealthDirect — bloating
8. Better Health Channel — wind and flatulence
9. PBS Schedule
10. Pimentel M et al. ACG 2020 Clinical Guideline: SIBO. AJG 2020;115:165
11. Rezaie A et al. H₂/CH₄ Breath Testing — North American Consensus. AJG 2017;112:775
12. Gatta L, Scarpignato C. Rifaximin meta-analysis for SIBO. Aliment Pharmacol Ther 2017
13. Pimentel M et al. Rifaximin for IBS-D — TARGET 1+2. NEJM 2011
14. Quigley EMM et al. AGA Clinical Practice Update on SIBO. Gastroenterology 2020